Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMARTEST: Dapagliflozin vs Metformin in Early Stage Type 2 Diabetes
NCT03982381Phase 4Completed
- Sponsor
- Uppsala University
- Start
- Sep 2019
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Uppsala University. Primary endpoint: Time to first occurrence of a confirmed composite endpoint of death, myocardial infarction, stroke, heart failure, diabetic nephropathy, retinopathy or foot ulcer. Started Sep 2019; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03982381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982381.